Success Metrics

Clinical Success Rate

100.0%

Based on 16 completed trials

Completion Rate

100%(16/16)

Active Trials

0(0%)

Results Posted

19%(3 trials)

Phase Distribution

Ph phase_1

14%

Ph phase_2

Ph phase_3

23%

Ph phase_4

32%

Ph not_applicable

18%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution21 total trials

Phase 1Safety & dosage

3(14.3%)

Phase 2Efficacy & side effects

2(9.5%)

Phase 3Large-scale testing

5(23.8%)

Phase 4Post-market surveillance

7(33.3%)

N/ANon-phased studies

4(19.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(16)

Other(6)

Detailed Status

Completed16

unknown6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (14.3%)

Phase 22 (9.5%)

Phase 35 (23.8%)

Phase 47 (33.3%)

N/A4 (19.0%)

Trials by Status

completed1673%

unknown627%

Recent Activity

0 active trials

Showing 5 of 22

completedphase_1

Rebamipide in Patients With Active Rheumatoid Arthritis

NCT05166304

unknownphase_3

Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients

NCT04649697

completedphase_2

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more

NCT05166304Phase 1

Rebamipide in Patients With Active Rheumatoid Arthritis

Completed

NCT04649697Phase 3

Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients

Unknown

NCT00463151Phase 2

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

Completed

NCT00233363Phase 2

Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome

Completed

NCT00233389Phase 4

Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

Completed

NCT04885751Phase 4

Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy

Unknown

NCT04550858

h.Pylori Ttt With Rebamipide

Unknown

NCT01759108Not Applicable

Rebamipide AND Sjögren Syndrome

Unknown

NCT02243618Not Applicable

The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer

Completed

NCT03608761Phase 4

Comparison Between Rebamipide 2% Versus Autologous Serum

Completed

NCT01549743Phase 1

The Pharmacokinetic Interaction Between Celecoxib and Rebamipide

Completed

NCT02755753Phase 4

A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis

Completed

NCT02134405Phase 4

Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia

Unknown

NCT01167101Not Applicable

Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

Completed

NCT00272467Phase 4

Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Completed

NCT02393430Phase 4

Clinical Effect of Rebamipide on Chronic Gastritis

Completed

NCT02106130Phase 1

A Drug Interaction Study of Mosapride and Rebamipide

Completed

NCT00996788Phase 3

Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis

Completed

NCT00576706Phase 3

PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity

Completed

NCT00862628Not Applicable

The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries

Unknown

Drug Details

Intervention Type: DRUG
Total Trials: 22